Artelo Biosciences ( (ARTL) ) has released its Q4 earnings. Here is a breakdown of the information Artelo Biosciences presented to its investors.
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways to address unmet needs in cancer, pain, dermatologic, and neurological conditions.
The company recently released its fiscal 2024 year-end financial results and provided a business update, highlighting significant progress in its clinical programs and financial performance.
Key developments include the advancement of ART26.12, a Fatty Acid Binding Protein inhibitor, with its Phase I study expected to conclude in Q2 2025. ART27.13 is progressing in the Phase 2 CAReS trial, targeting cancer anorexia, with initial data anticipated by the end of Q2 2025. Additionally, ART12.11 is set to begin human studies in the second half of 2025, offering a novel approach to treating anxiety and depression. Financially, Artelo reported a net loss of $9.8 million for 2024, slightly higher than the previous year, with research and development expenses increasing to $6.0 million.
Looking ahead, Artelo Biosciences is poised to achieve important clinical milestones in 2025, with management expressing optimism about the potential of their innovative therapies to address significant unmet medical needs.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com